EP3316883A4 - Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use - Google Patents

Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use Download PDF

Info

Publication number
EP3316883A4
EP3316883A4 EP15897348.7A EP15897348A EP3316883A4 EP 3316883 A4 EP3316883 A4 EP 3316883A4 EP 15897348 A EP15897348 A EP 15897348A EP 3316883 A4 EP3316883 A4 EP 3316883A4
Authority
EP
European Patent Office
Prior art keywords
inhibitors
methods
drug screen
throughput drug
fkbp51 protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP15897348.7A
Other languages
German (de)
French (fr)
Other versions
EP3316883A1 (en
Inventor
Jonathan Jacob Sabbagh
Chad Dickey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of South Florida
Original Assignee
University of South Florida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of South Florida filed Critical University of South Florida
Publication of EP3316883A1 publication Critical patent/EP3316883A1/en
Publication of EP3316883A4 publication Critical patent/EP3316883A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP15897348.7A 2015-06-30 2015-06-30 Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use Withdrawn EP3316883A4 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/038664 WO2017003469A1 (en) 2015-06-30 2015-06-30 Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use

Publications (2)

Publication Number Publication Date
EP3316883A1 EP3316883A1 (en) 2018-05-09
EP3316883A4 true EP3316883A4 (en) 2019-06-12

Family

ID=57608833

Family Applications (1)

Application Number Title Priority Date Filing Date
EP15897348.7A Withdrawn EP3316883A4 (en) 2015-06-30 2015-06-30 Inhibitors of the fkbp51 protein from a high-throughput drug screen and methods of use

Country Status (2)

Country Link
EP (1) EP3316883A4 (en)
WO (1) WO2017003469A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102051624B1 (en) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 Pharmaceutical composition for treatment of neurodegenerative brain disease comprising triflupromazine or pharmacurically acceptable salt thereof as an active ingredient

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091900A1 (en) * 2011-12-22 2013-06-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
WO2015039758A1 (en) * 2013-09-19 2015-03-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Selective fkbp51 ligands for treatment of psychiatric disorders
WO2015110271A1 (en) * 2014-01-24 2015-07-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1392262A1 (en) * 2001-05-24 2004-03-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
WO2011054399A1 (en) * 2009-11-06 2011-05-12 Avail Gmbh Improvement of the glucocorticoid receptor function in asthma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013091900A1 (en) * 2011-12-22 2013-06-27 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Pipecolate-diketoamides for treatment of psychiatric disorders
WO2015039758A1 (en) * 2013-09-19 2015-03-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Selective fkbp51 ligands for treatment of psychiatric disorders
WO2015110271A1 (en) * 2014-01-24 2015-07-30 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Diazabicyclo[4.3.1]decane derivatives for treatment of psychiatric disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
O'LEARY J ET AL: "FKBP5 gene deletion prevents susceptibility to depression", SOCIETY FOR NEUROSCIENCE ABSTRACT VIEWER AND ITINERARY PLANNER, vol. 41, 2011, & 41ST ANNUAL MEETING OF THE SOCIETY-FOR-NEUROSCIENCE; WASHINGTON, DC, USA; NOVEMBER 12 -16, 2011, XP002787677 *
See also references of WO2017003469A1 *
STRANG R R: "Experiences with cogentin in the treatment of Parkinsonism. A one-year controlled study of 94 patients.", ACTA NEUROLOGICA SCANDINAVICA 1966, vol. 41, no. 4, 1966, pages 413 - 418, XP002787676, ISSN: 0001-6314 *
TISLOW R F: "USEFULNESS OF ANTI CHOLINERGIC DRUGS IN SUPPRESSING SYMPTOMS OF DEPRESSION IN MAN ABSTRACT BENZTROPINE CENT STIM TRIHEXYPHENIDYL CENT STIM BIPERIDEN CENT STIM", FEDERATION PROCEEDINGS, FEDERATION OF AMERICAN SOCIETIES FOR EXPERIMENTAL BIOLOGY, US, vol. 28, no. 2, 1 January 1969 (1969-01-01), pages 728, XP009510075, ISSN: 0014-9446 *

Also Published As

Publication number Publication date
WO2017003469A1 (en) 2017-01-05
EP3316883A1 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
EP3700527A4 (en) Papd5 inhibitors and methods of use thereof
EP3600318A4 (en) Methods of using ehmt2 inhibitors
EP3541932A4 (en) Inhibitors of crispr-cas9
EP3383430A4 (en) Antibodies and methods of use thereof
EP3429591A4 (en) Substituted inhibitors of menin-mll and methods of use
EP3280441A4 (en) Anti-sortilin antibodies and methods of use thereof
EP3510040A4 (en) Ectonucleotidase inhibitors and methods of use thereof
EP3371810A4 (en) Apparatuses and methods including memory and operation of same
EP3268369A4 (en) Anti-alphavbeta1 integrin inhibitors and methods of use
EP3245291A4 (en) Novel micro-dystrophins and related methods of use
EP3280419A4 (en) Indazole and azaindazole btk inhibitors
EP3240799A4 (en) S-alkylated hepcidin peptides and methods of making and using thereof
EP3134091A4 (en) Irak inhibitors and uses thereof
EP3558998A4 (en) Ectonucleotidase inhibitors and methods of use thereof
EP3319611A4 (en) Oxysterols and methods of use thereof
EP3331530A4 (en) Mthfd2 inhibitors and uses thereof
EP3172617A4 (en) Display device and method of manufacturing the same
EP3344803A4 (en) Modular polypeptide libraries and methods of making and using same
EP3319610A4 (en) Oxysterols and methods of use thereof
EP3319612A4 (en) Oxysterols and methods of use thereof
EP3727371A4 (en) Gpcr heteromer inhibitors and uses thereof
EP3094346A4 (en) Vista antagonist and methods of use
EP3320388A4 (en) Display device and method of manufacturing thereof
EP3710430A4 (en) Acss2 inhibitors and methods of use thereof
EP3265476A4 (en) Protoxin-ii variants and methods of use

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DICKEY, CHAD

Inventor name: SABBAGH, JONATHAN JACOB

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/445 20060101ALI20190114BHEP

Ipc: A61K 31/498 20060101ALI20190114BHEP

Ipc: A61P 25/28 20060101ALI20190114BHEP

Ipc: A61K 31/415 20060101ALI20190114BHEP

Ipc: A61K 31/439 20060101AFI20190114BHEP

Ipc: A61P 25/00 20060101ALI20190114BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20190514

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/498 20060101ALI20190508BHEP

Ipc: A61K 31/415 20060101ALI20190508BHEP

Ipc: A61K 31/439 20060101AFI20190508BHEP

Ipc: A61P 25/00 20060101ALI20190508BHEP

Ipc: A61K 31/445 20060101ALI20190508BHEP

Ipc: A61P 25/28 20060101ALI20190508BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20200812

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20201223